Omnipaque

Common Uses

Omnipaque is a radiopaque contrast medium that contains iodine. It is used to enhance the quality of images produced during various diagnostic procedures, such as X-rays and CT scans. It works by temporarily changing the way imaging beams interact with the body, allowing specific areas to stand out against surrounding tissues.

Diagnostic Procedures

This medication is used for several types of imaging tests depending on how it is administered:

• Blood Vessel Imaging: Used in angiography or arteriography to visualize the heart, brain, kidneys, and blood vessels in the limbs.
• Computed Tomography (CT): Used to improve the detail of scans of the head and body.
• Spinal Imaging: Used in myelography to view the spinal cord and nerve roots.
• Urinary Tract Imaging: Used in urography to examine the kidneys, ureters, and bladder.
• Joint Imaging: Used in arthrography to look inside joints.
• Body Cavity Imaging: Used to examine the uterus and fallopian tubes or the bladder to identify abnormalities.

Gastrointestinal Uses

When taken by mouth or given rectally, Omnipaque is used to help doctors examine the stomach and intestines. This is often done during CT scans or fluoroscopy to check for blockages, leaks, or other structural issues in the digestive tract.

Mechanism of Action

Omnipaque belongs to a group of medicines known as radiopaque contrast media. It contains iodine, which is a substance that absorbs X-rays. By absorbing these rays, the medication helps create a clear picture of internal organs and tissues that are usually difficult to see on standard imaging.

When the medication is present in the body, it blocks X-ray beams as they pass through. This causes the areas containing the drug to appear bright or white on the resulting images, providing a sharp contrast against the surrounding tissues. This process allows healthcare providers to see the size, shape, and condition of various structures.

The way the medication works depends on how it is administered:

• Injected into blood vessels: It highlights the flow of blood and shows the structure of arteries and veins.
• Injected into the spine: It allows doctors to see the spinal cord and nerve roots.
• Taken by mouth or through a tube: It outlines the digestive tract or specific organs like the bladder or joints.

Once the imaging procedure is complete, the body typically filters the medication out through the kidneys, and it is passed out of the body in the urine.

Common Side Effects

Many people do not experience significant side effects after receiving Omnipaque. When they do occur, common reactions may include:

• Nausea or vomiting
• Headache
• Dizziness
• A sudden feeling of warmth or flushing
• Mild skin rash or itching
• An unusual or metallic taste in the mouth
• Pain, coldness, or burning at the site of injection
• Stomach cramps or diarrhea (if taken orally or rectally)

Serious Side Effects

While rare, some side effects can be life-threatening. Seek emergency medical care immediately if you notice:

• Symptoms of a severe allergic reaction, such as hives, swelling of the face or throat, and difficulty breathing
• Chest pain, shortness of breath, or an irregular heartbeat
• Seizures, confusion, or extreme drowsiness
• Vision changes or speech problems
• Signs of kidney trouble, such as decreased urination or swelling in the legs and feet
• Severe skin reactions, including redness, blistering, or peeling
• Wheezing or a feeling of tightness in the chest
• Severe back pain, stiffness, or numbness (if given via the spine)

Severe Allergic Reactions

Serious and sometimes fatal hypersensitivity reactions, including anaphylaxis, can occur. These reactions may happen even if a patient has not previously reacted to contrast media. Medical personnel should be prepared to manage emergency situations during and after administration.

Kidney Function

Iohexol can cause contrast-induced nephropathy, which is a decline in kidney function following the use of contrast agents. The risk is higher for patients with certain conditions, including:

• Pre-existing kidney disease
• Diabetes mellitus
• Dehydration
• Advanced age
• Congestive heart failure

Neurological Risks

When used for imaging of the spine (intrathecal use) or blood vessels, there is a risk of serious neurological events such as seizures, encephalopathy, coma, or stroke. Patients with a history of epilepsy or those taking medications that lower the seizure threshold may be at increased risk.

Thyroid Complications

Contrast agents containing iodine can trigger a thyroid storm in patients with hyperthyroidism or an overactive thyroid gland. In infants, especially those born prematurely, there is a risk of temporary hypothyroidism (low thyroid hormone levels) following exposure to iodinated contrast.

Cardiovascular and Blood Disorders

Iohexol may cause serious heart-related events, including cardiac arrest, arrhythmias, or pulmonary edema. In patients with sickle cell disease, the administration of contrast media may promote the sickling of red blood cells.

Other Precautions

• Pheochromocytoma: Administration may cause a severe and sudden increase in blood pressure in patients with this type of adrenal gland tumor.
• Extravasation: If the medication leaks into the surrounding tissue during injection, it can cause local tissue irritation or damage.
• Hydration: Adequate hydration before and after the procedure is important to reduce the risk of kidney injury.

Pregnancy

There are no adequate and well-controlled studies of Omnipaque in pregnant women. Animal studies involving high doses of iohexol did not show evidence of fetal harm or fertility issues. Because animal data is not always representative of human effects, this medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding

Iohexol is excreted in human breast milk in very small quantities. It is also poorly absorbed from the gastrointestinal tract, meaning very little of the drug is likely to be absorbed by a nursing infant. While many clinical guidelines suggest that interrupting breastfeeding is not necessary after the administration of Omnipaque, you should discuss your specific situation with your healthcare provider.

Available Forms

Omnipaque (iohexol) is supplied as a clear, colorless to pale yellow sterile solution. It is available in several concentrations based on the amount of organically bound iodine per milliliter (mgI/mL).

• Injection: Used for intravenous, intra-arterial, and intrathecal administration.
• Oral Solution: Used for gastrointestinal imaging.
• Body Cavity Solution: Used for imaging specific areas like the bladder or joints.

Strengths

The medication is provided in the following iodine concentrations:

• 140 mgI/mL
• 180 mgI/mL
• 240 mgI/mL
• 300 mgI/mL
• 350 mgI/mL

The solution is packaged in various containers, including single-dose glass vials, plastic bottles, and larger pharmacy bulk packages intended for multiple uses in a clinical setting.

FDA Approval Status

Omnipaque (iohexol) is approved by the U.S. Food and Drug Administration (FDA) as a nonionic, water-soluble contrast medium. It is used in both adult and pediatric patients to enhance the visibility of internal organs, blood vessels, and tissues during diagnostic tests.

Boxed Warning

The FDA has issued a boxed warning for Omnipaque regarding the risk of accidental spinal (intrathecal) injection. Certain concentrations, specifically Omnipaque 140 and Omnipaque 350, are not approved for injection into the spinal canal. Accidental administration of these concentrations into the spine can lead to serious medical emergencies, including seizures, brain hemorrhage, or death.

Approved Indications

Omnipaque is FDA-approved for a wide range of diagnostic procedures, including:

• Intravascular imaging: Visualizing the heart, blood vessels, and urinary tract.
• Intrathecal imaging: Visualizing the spinal cord (myelography) and associated structures using specific approved concentrations.
• Body cavity imaging: Visualizing the joints, pancreas, and gastrointestinal tract.
• Computed Tomography (CT): Enhancing images of the head and body during CT scans.

Safety and Monitoring

The FDA monitors Omnipaque for potential risks such as severe allergic reactions (anaphylaxis), kidney injury (nephrotoxicity), and thyroid dysfunction in infants. While there is no Risk Evaluation and Mitigation Strategy (REMS) required, the medication must be administered by healthcare professionals in settings equipped to manage emergency reactions.

Use During Pregnancy

The safety of Omnipaque (iohexol) during pregnancy has not been fully established. While animal reproduction studies have not shown evidence of harm to the fetus or impaired fertility, these results do not always predict the response in humans. Because there are no well-controlled studies in pregnant women, this medication should be administered only if clearly needed and after a careful risk-benefit analysis by a healthcare provider.

Potential Risks

Iodinated contrast agents like Omnipaque are known to cross the placenta. Although the specific risks to a human fetus are not well-documented, healthcare providers generally consider the following:

• Fetal Thyroid Function: There is a theoretical concern that iodine-containing contrast agents could affect the development or function of the fetal thyroid gland.
• Necessity of Imaging: Diagnostic procedures using contrast are typically postponed until after delivery unless the medical situation is urgent.

If you are pregnant or planning to become pregnant, notify your doctor or radiologist before undergoing any imaging procedure that requires Omnipaque. They will determine if the diagnostic information gained from the scan is essential for your care during pregnancy.